Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies

Keyphrases

• Newly Diagnosed 100%
• Survival Analysis 100%
• Meta-analysis 100%
• Acute Myeloid Leukemia 100%
• Hypomethylating Agents 100%
• Systematic Meta-analysis 100%
• Survival Data 100%
• Venetoclax 100%
• Azacitidine 40%
• Leukemia Patients 30%
• Different Characteristics 20%
• Survival Curve 20%
• Median Survival 20%
• Adherence to Therapy 20%
• Intensive Chemotherapy 20%
• Expected Outcomes 10%
• Clinical Trials 10%
• Survival Rate 10%
• Induction Chemotherapy 10%
• Inclusion Criteria 10%
• Standard of Care 10%
• Log-rank Test 10%
• Nineteen 10%
• Newly Diagnosed Patients 10%
• Kaplan-Meier Curve 10%
• Decitabine 10%
• Alternative Regimens 10%
• Individual Survival 10%
• Azacytidine 10%

Medicine and Dentistry

• Meta-Analysis 100%
• Acute Myeloid Leukemia 100%
• Systematic Review 100%
• Hypomethylating Agent 100%
• Venetoclax 100%
• Azacitidine 50%
• Survival Rate 30%
• Patient Compliance 20%
• Clinical Trial 10%
• Randomized Controlled Trial 10%
• Induction Chemotherapy 10%
• Kaplan Meier Method 10%
• Log Rank Test 10%
• Decitabine 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Myeloid Leukemia 100%
• Venetoclax 100%
• Azacitidine 50%
• Survival Rate 30%
• Chemotherapy 30%
• Clinical Trial 10%
• Randomized Controlled Trial 10%
• Decitabine 10%